Efficacy On The Surgical Treatment For Advanced Gastric Cancer With MFOLFOX6Regimen As Neoadjuvant Chemotherapy

Objective:To study the mFOLFOX6scheme of neoadjuvant chemotherapy foradvanced gastric cancer resection rate and the effect of perioperative complications.Methods:Prospective randomized controlled method is applied to analyze theqinghai university affiliated hospital gastrointestinal tumor surgery since March2014-02,201160cases in accordance with the set of conditions in patients withadvanced gastric cancer. According to the set of order according to random numbertable method divided into observation group (30cases) and control group (30cases).Before each patient treatment were performed including chest X-ray,electrocardiogram (ecg), abdominal colour to exceed, stomach CT, blood routine,biochemical, a full set of tumor markers such as check evaluation. Observationgroup of30cases of patients with preoperative be mFOLFOX6scheme neoadjuvantchemotherapy2-3cycles, curative effect evaluation of clinical partially effective(Partial Response, PR) or perfectly valid (Complete Response, CR) surgicaltreatment. The control group30routine surgical treatment alone.Results:(1)To observe the clinical effective rate of neoadjuvant chemotherapy groupmFOLFOX6scheme53.33%, observation group of patients with chemotherapy welltolerated, adverse reactions mainly in bone marrow suppression, gastrointestinalreactions;(2)The observation group R0resection rate (93.3%), D2lymph nodeQingSaoLv (86.7%) is significantly higher than control group in R0resection(66.7%), D2lymph node QingSaoLv (63.3%)(P <0.05); Postoperative lymph nodepositive rate (12.5%) of the observation group was obviously lower than controlgroup in postoperative lymph node positive rate (39.3%)(P <0.05); Postoperativepathological observation group, staging (≦stage T326cases, T4a2cases; Nstaging: N0stage22cases,6patients with≧N1; M stages:2cases; pathologicalstaging:﹤Ⅲ phase22cases,≧Ⅲ8cases) Was lower than that in group onpostoperative pathology, staging (≦stage T312cases, T4a18cases; N staging: N0stage12cases,18cases of≧N1; pathological staging:﹤Ⅲ12cases,≧Ⅲ18cases)(P<0.05);(3)Observation group operating time (132.8±52.6min), intraoperative blood loss, postoperative length of hospital stay (54.2±32.3ml)(10.3±2.1d), theincidence of postoperative complications (10.94%) and control group in operationtime (128.8±59.6min), intraoperative blood loss, postoperative hospital stay(146.8±42.6ml)(11.6±1.6d), the incidence of postoperative complications (8.9%) nosignificant difference (P>0.05).Conclusion:(1)mFOLFOX6solutions for advanced gastric cancer neoadjuvantchemotherapy high efficient, good tolerance and compliance;(2)New adjuvantchemotherapy as a treatment for advanced gastric cancer, a new model does notincrease the surgical complications;(3)The new adjuvant chemotherapy for patientswith advanced gastric cancer would improve the R0resection rate and reduce therate of lymph node metastasis, postoperative pathological drop period effect afterneoadjuvant chemotherapy, can improve the prognosis.